MX2021008507A - Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas. - Google Patents

Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.

Info

Publication number
MX2021008507A
MX2021008507A MX2021008507A MX2021008507A MX2021008507A MX 2021008507 A MX2021008507 A MX 2021008507A MX 2021008507 A MX2021008507 A MX 2021008507A MX 2021008507 A MX2021008507 A MX 2021008507A MX 2021008507 A MX2021008507 A MX 2021008507A
Authority
MX
Mexico
Prior art keywords
lilrb3
binding molecules
uses therefor
antibodies
pharmaceutical compositions
Prior art date
Application number
MX2021008507A
Other languages
English (en)
Spanish (es)
Inventor
Jacqueline M Mason
Mark R Bray
Richard Brokx
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2021008507A publication Critical patent/MX2021008507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021008507A 2019-01-18 2020-01-16 Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas. MX2021008507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794064P 2019-01-18 2019-01-18
PCT/CA2020/050042 WO2020146946A1 (en) 2019-01-18 2020-01-16 Lilrb3-binding molecules and uses therefor

Publications (1)

Publication Number Publication Date
MX2021008507A true MX2021008507A (es) 2021-09-21

Family

ID=71612981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008507A MX2021008507A (es) 2019-01-18 2020-01-16 Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.

Country Status (14)

Country Link
US (1) US12404327B2 (enExample)
EP (1) EP3911680A4 (enExample)
JP (1) JP7631203B2 (enExample)
KR (1) KR20210118116A (enExample)
CN (1) CN113454123A (enExample)
AU (1) AU2020209367A1 (enExample)
BR (1) BR112021014102A2 (enExample)
CA (1) CA3126295A1 (enExample)
EA (1) EA202192008A1 (enExample)
IL (1) IL284781A (enExample)
MX (1) MX2021008507A (enExample)
SG (1) SG11202107663UA (enExample)
TW (1) TWI852980B (enExample)
WO (1) WO2020146946A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
CN116963747A (zh) * 2020-12-03 2023-10-27 德克萨斯大学体系董事会 用于鉴定lilrb阻断抗体的方法
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CN115925941B (zh) * 2022-06-08 2026-04-03 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
AU2011207253B2 (en) * 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3256163A4 (en) * 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US11787858B2 (en) * 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112021014102A2 (pt) 2021-09-21
US20220089723A1 (en) 2022-03-24
TW202031685A (zh) 2020-09-01
KR20210118116A (ko) 2021-09-29
WO2020146946A1 (en) 2020-07-23
US12404327B2 (en) 2025-09-02
JP2022517809A (ja) 2022-03-10
SG11202107663UA (en) 2021-08-30
CA3126295A1 (en) 2020-07-23
AU2020209367A1 (en) 2021-08-19
TWI852980B (zh) 2024-08-21
JP7631203B2 (ja) 2025-02-18
EA202192008A1 (ru) 2021-10-21
IL284781A (en) 2021-08-31
CN113454123A (zh) 2021-09-28
EP3911680A1 (en) 2021-11-24
EP3911680A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
PH12019502870A1 (en) Small molecule modulators of human sting
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA201790267A1 (ru) Новые модуляторы киназ
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
MX2022000712A (es) Moduladores de nlrp3.
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
EA202092518A1 (ru) Композиции и способы лечения рака
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
MX2023010661A (es) Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas.
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
PH12022552447A1 (en) Nlrp3 modulators
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина